T helper 1 and T helper 17 cell differentiation pathways (Th1/Th17 pathways)

The T helper 1 (Th1) and T helper 17 (Th17) cell differentiation pathways are fundamental biological processes that direct the specialization of naive CD4+ T cells into distinct effector lineages. Th1 differentiation is primarily induced by interleukin-12 (IL-12) and interferon-gamma (IFN-gamma), activating the transcription factor T-bet to promote cellular immunity against intracellular pathogens (KEGG, 2024). Conversely, Th17 differentiation is driven by cytokines such as IL-6, TGF-beta, and IL-23, which trigger the expression of ROR-gamma-t and the production of IL-17 and IL-22 to combat extracellular bacteria and fungi (StatPearls, 2023). Dysregulation of the balance between these pathways is a central driver in the pathogenesis of numerous autoimmune and chronic inflammatory conditions, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease (Nature Reviews Immunology, 2020). Therapeutic intervention often involves the use of monoclonal antibodies to neutralize specific cytokines like IL-17 or IL-23, or small molecule inhibitors to block downstream signaling through the JAK/STAT pathway (PubMed, 2021). While these treatments are highly effective in reducing inflammation, they are associated with an increased risk of specific infections and require careful patient monitoring for safety.

Other names

Th1 and Th17 cell differentiationTh1/Th17 axisT-helper cell differentiation pathwaysTh1/Th17 signaling cascade

Inhibition of pro-inflammatory cytokines (IL-12, IL-23, IL-17), blockade of cytokine receptors, or inhibition of intracellular signaling transducers (JAK/STAT) to prevent T-cell lineage commitment and effector function.